VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$4.70 USD
-0.02 (-0.42%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.68 -0.02 (-0.43%) 5:44 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
VTGN 4.70 -0.02(-0.42%)
Will VTGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VTGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VTGN
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
VTGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
Other News for VTGN
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen says PH15 shows statistically significant improvement in reaction time
Vistagen reports positive results for mental fatigue treatment
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression
7 Stocks Under $15 Predicted to Boom in the Next 2 Years